Panelists offered perspectives on efforts currently underway to move the healthcare system toward one that rewards innovation, delivers better quality and puts the patient at the center of the value equation.
Mylan CEO Heather Bresch on Tuesday addressed the annual meeting of the Association for Accessible Medicines (the newly adopted name of the former Generic Pharmaceutical Association), calling on generics makers to “produce the savings for this country, not the costs,” according to WAJR. Bresch said that the AAM’s new name, which comes alongside the launch of a new campaign “Keeping Medicines Within Reach” shows “the dramatic shift in how healthcare is being delivered in our country, and the increasing importance for patients approaching the pharmacy counter to experience the true savings that our medicines provide.” (WAJR)
Its new identity will improve recognition that the generic and biosimilar medicines industry is one of “the nation's great health care success stories, and that competition from generics and biosimilars lowers the cost of medicine.”
Noting that Price will play a key role in selecting the next commissioner for the Food and Drug Administration, the Consumer Healthcare Products Associaton offered several qualities that would embody an ideal candidate.